Integral Diagnostics (ASX:IDX) released its financial results for the half-year ended Dec. 31, 2025, reporting significant growth across its key performance metrics.
The medical imaging provider saw revenue and other income climb to $393.5 million, representing a 55.6% increase compared to the prior corresponding period.
The surge was bolstered by the integration of Capitol Health, which contributed to the group's operations following its acquisition in late 2024.
Operating EBITDA rose by 75.6% to $81.1 million, with the operating margin expanding from 18.3% to 20.6%.
Operating net profit after tax experienced a substantial jump of 154.6%, reaching $22.3 million.
Statutory NPAT was recorded at a lower $9 million due to $13.3 million in one-off costs associated with transaction and merger integration, restructuring, and share-based expenses.
Management noted that merger integration remains on track, with annualised synergies now expected to exceed $14 million, surpassing initial estimates.
The group's balance sheet appears stabilised, with net debt to operating EBITDA reducing to 2.5x.
Shareholders are set to receive a fully franked interim dividend of 3.3 cents per share, payable on April 2.
At the time of reporting, Integral Diagnostics' share price was $2.26.